ARPA-H launched the ADVOCATE program to fund health technology companies building AI agents intended for authorized clinical use, aiming to accelerate agentic tools for real-world care. The initiative follows ARPA-H’s broader role in backing biomedical innovations, with ADVOCATE positioned as a direct pipeline for operational AI. The agency’s framing centers on deployment in environments where oversight, validation, and regulatory authorization are needed, rather than treating AI capability as equivalent to integration readiness. Separately, FDA officials also signaled openness to regulatory flexibility for evaluating psychedelic therapies, including the potential use of comparators beyond placebo—underscoring an agency posture that can accommodate nontraditional clinical development designs. For the sector, these moves suggest both higher scrutiny on safety and performance and a pathway to faster iteration cycles, as long as companies can meet evidentiary expectations.